BTSG Filings — Brightspring Health Services, Inc. - FilingSpy
BTSG
Brightspring Health Services, Inc.
A home-and-community healthcare company that fills prescriptions through its pharmacy network and delivers nursing, hospice, rehab, and personal care in people's homes across all fifty states. It grew out of ResCare, founded in 1974 to serve adults with developmental disabilities, and took the BrightSpring name in 2019 after merging with pharmacy giant PharMerica. That name nods to fresh starts and growth—a fitting pick for a company built on caring for complex patients outside hospital walls.
Pharmacy Solutions gross margin rose to 9.5% in Q2, reversing a multi-year decline, while the Community Living sale proceeds pushed cash to $550M.
Pharmacy Solutions held at 9.5%, confirming the reversal that began last quarter after years of compression. rose 23% to $3.87 billion and reached $84.3 million, up from $19.9 million a year ago, as the mix shift toward higher-margin Infusion and Specialty Pharmacy products continued and fell. The Community Living divestiture proceeds are in hand, is down, and the margin story has changed.
Key takeaways
Pharmacy Solutions was 9.5%, unchanged from Q1 2026 and up from 8.4% a year ago, as a favorable mix shift toward higher-margin Infusion and Specialty Pharmacy products offset lower Home and Community Pharmacy tied to the Inflation Reduction Act.
Consolidated rose 23.0% to $3.87 billion, with Pharmacy Solutions up 22.1% on a 30.1% increase in Specialty and Infusion Pharmacy revenue and Provider Services up 30.3%, including $77.9 million from the Amedisys and LHC Branches acquisition.
Section summaries
Management's Discussion and Analysis
BrightSpring Q2 2026 revenue grew 23% to $3.9B, driven by Pharmacy Solutions and Provider Services, with Adjusted EBITDA up 44%.
⌄
Consolidated rose 23.0% to $3.9B, with Pharmacy Solutions up 22.1% to $3.4B and Provider Services up 30.3% to $466M.
was $84.3 million, up from $19.9 million a year ago, helped by higher and a 4.9% decline in to $36.9 million following a $300 million debt paydown and refinancing of the First Lien Facility.
was $43.9 million, down 10.5% , while fell 39.6% to $14.9 million as movements offset higher earnings.
Cash and equivalents stood at $550.4 million, up from $22.8 million a year ago, reflecting the $810.9 million in Community Living divestiture proceeds that closed in Q1 2026, while fell 13.3% to $2.15 billion.
Company improved to 2.15x from 2.99x at year-end 2025, and total liquidity was $1.03 billion at quarter-end.
What changed
The multi-year decline in Pharmacy Solutions that earlier filings flagged as a primary concern has now reversed: after holding at 8.4% in Q2 2025 and 9.5% in Q1 2026, the margin remained at 9.5% in Q2 2026, confirming the stabilization and improvement driven by a mix shift toward higher-margin Infusion and Specialty Pharmacy products.
The $835 million Community Living divestiture, flagged in every filing since FY 2024 as a key catalyst, closed in Q1 2026, generating $810.9 million in proceeds. The proceeds reduced to $2.15 billion from $2.48 billion a year ago, and fell 4.9% in Q2 as a result.
Home Health Care average daily census growth, which had decelerated from 16.1% in Q3 2024 to 3.3% in Q3 2025, rose to 52.3% in Q1 2026 following the Amedisys/LHC acquisition. The Q2 filing does not provide a discrete census growth figure, but Provider Services rose 30.3%, with $77.9 million of the increase attributed to the acquisition and $30.5 million to organic volume and rate gains.
SG&A expenses, which rose 19.3% in Q2 2025 on acquisition-related costs and , remained elevated in Q2 2026 as the company cited higher public company and IT costs that partially offset growth, though a specific SG&A figure is not broken out in the provided sections.
What to watch
Whether Pharmacy Solutions holds at 9.5% or continues to rise as the mix shift toward Infusion and Specialty Pharmacy products deepens further.
The trajectory of Provider Services now that the initial Amedisys/LHC acquisition contribution is in the base, and whether the $30.5 million in organic volume and rate gains accelerates or fades.
The level of integration costs tied to the Amedisys/LHC acquisition and whether they keep corporate costs elevated in coming quarters.
The impact of the Inflation Reduction Act on Home and Community Pharmacy , which declined 8.0% in Q2, and whether that intensifies.
Pharmacy Solutions growth was fueled by a 30.1% increase in Specialty and Infusion Pharmacy , partially offset by an 8.0% decline in Home and Community Pharmacy due to the Inflation Reduction Act.
Provider Services growth included a $77.9M contribution from the Amedisys and LHC Branches acquisition and $30.5M from organic volume and rate increases.
increased to $86.6M from $8.5M, and rose 44.2% to $205.5M, with growth partially offset by higher public company and IT costs.
decreased 4.9% to $36.9M due to lower variable rates and reduced debt following a $300M paydown and refinancing of the First Lien Facility.
Total liquidity stood at $1.03B at quarter-end, and company improved to 2.15x from 2.99x at year-end 2025.
From time to time, we are involved in various legal and/or administrative proceedings and subject to claims that arise in the ordinary course of business. We do not believe the ultimate liability, if any, for outstanding proceedings or claims, individually or in the aggregate, i…
⌄
From time to time, we are involved in various legal and/or administrative proceedings and subject to claims that arise in the ordinary course of business. We do not believe the ultimate liability, if any, for outstanding proceedings or claims, individually or in the aggregate, in excess of amounts already provided in our consolidated financial statements, will have a material adverse effect on our business, financial condition, or results of operations. It is reasonably possible that an adverse determination might have an impact on a particular period. Regardless of the outcome, litigation has the potential to have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
There have been no material changes to the risk factors affecting our business, financial condition, or results of operations from those set forth under the heading “Summary Risk Factors” or in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended…
⌄
There have been no material changes to the risk factors affecting our business, financial condition, or results of operations from those set forth under the heading “Summary Risk Factors” or in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.